Currently, GLP-1R agonists used in the treatment of AD models include (Val8)GLP-1, GLP-1(9-36)amide, GLP-1(7-36)amide, CJC-1131, Geniposide, Exendin(5-39), Exendin-4, NLY01 (engineered exendin-4), liraglutide, Lixisenatide, Dulaglutide, Exenatide, GLP-1, dual GLP-1/GIP receptor agonist (DA-JC4, DA-JC1, DA5-CH, DA-CH3), GLP-1/GIP/Gcg receptor triagonist (triagonist, TA), dual GLP-1 and Gcg receptor agonist (oxyntomodulin) (144, 147, 148, 150, 171, 180, 186, 189, 194, 218, 219, 228, 235, 237, 238, 241, 242)
Reducing visceral fat is essential for improving overall health and lowering BMI (Body Mass Index)
Vision changes: Sudden or worsening changes in vision, especially in people with type 2 diabetes, should be evaluated by a provider as soon as possible
By restoring the brain's delicate redox balance and supporting the critical excitatory and inhibitory neurotransmitter functions of glycine at the NMDA receptors, patients frequently report significant, life-altering improvements in cognitive stamina, mental clarity, and a marked reduction in overwhelming neurological fatigue
